Molina Healthcare (MOH) Stock Valuation After Illinois Medicaid Contract Win And Margin Recovery Signals

Molina Healthcare (MOH) is back on investor radar after its Illinois subsidiary secured a HealthChoice Illinois Medicaid Managed Care contract, along with improving Q1 2026 margins and fresh attention from recent analyst actions.

See our latest analysis for Molina Healthcare.

The recent 36.7% 90 day share price return and 8.3% 30 day share price return suggest momentum has picked up around the Illinois Medicaid contract win, Q1 2026 margin improvement and renewed analyst attention, even though the 1 year total shareholder return is down 32.8%.

If Molina’s move has you looking beyond a single managed care stock, this is a good moment to scan for other healthcare opportunities through 40 healthcare AI stocks

So with the stock up sharply over 90 days, trading around US$200.28 and carrying a mixed track record over 1 and 5 years, is MOH still undervalued, or has the market already priced in future growth?

Most Popular Narrative: 33.7% Overvalued

The most widely followed valuation narrative for Molina Healthcare pegs fair value at $149.76, well below the last close at $200.28. This frames the Illinois contract win and recent margin commentary against a higher current market price.

Molina’s disciplined approach to medical cost management, amidst enhancements in the rate environment, is likely to stabilize or improve net margins by mitigating the impact of rising medical costs.

Read the complete narrative.

Want to see what sits behind that confidence in margins and future earnings power? The narrative leans on specific revenue, profit and valuation assumptions that might surprise you.

Result: Fair Value of $149.76 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the narrative still hinges on Medicaid funding remaining supportive and on medical cost trends not eroding already thin 1.1% assumed profit margins.

Find out about the key risks to this Molina Healthcare narrative.

Another View: Cash Flows Paint A Very Different Picture

While the most popular narrative sees Molina Healthcare as 33.7% overvalued relative to a US$149.76 fair value, our DCF model points the other way entirely. On this view, the stock at US$200.28 trades about 68% below an estimated cash flow value of US$625.09, raising a very different question about risk and opportunity.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Molina Healthcare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

This mix of optimism and concern sets a clear tension. Consider moving quickly, reviewing the underlying drivers for yourself, and weighing the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Molina has sharpened your focus on healthcare, do not stop here. Widening your search now can help you spot opportunities others might miss.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com